## Specific Phobia: Neurobiology, Genetics, and Treatment ### Genetic and Neurobiological Basis **High-Yield:** Specific phobias have **higher heritability (~40%)** compared to social anxiety disorder (~30%) and generalized anxiety disorder (~25%). This reflects a stronger genetic predisposition to fear conditioning. **Key Point:** The amygdala (fear center) and insula (interoceptive awareness) show robust hyperactivation during phobic stimulus exposure on fMRI, supporting the fear-conditioning model. ### Evidence-Based Treatment Hierarchy | Treatment | Evidence | Efficacy | First-Line? | |---|---|---|---| | Exposure therapy (in vivo) | Extensive RCTs | 60–80% remission | **YES** | | Cognitive restructuring | Moderate | 40–60% improvement | Adjunct | | SSRIs (paroxetine, sertraline) | Limited evidence | 30–40% improvement | **NO** | | Benzodiazepines | Poor long-term data | Temporary relief only | Avoid | **Clinical Pearl:** Exposure therapy is the **gold standard** for specific phobias. In vivo exposure (actual feared situation) is superior to imaginal exposure. Remission rates of 60–80% are well-established across meta-analyses. ### Why Pharmacotherapy is NOT First-Line **Warning:** SSRIs show **modest efficacy** (30–40% response) in specific phobia and are **inferior to psychotherapy**. Unlike panic disorder or social anxiety disorder, pharmacotherapy is not recommended as first-line for specific phobia. Exposure therapy alone is preferred. **Mnemonic:** **SEEP** — Specific phobia → Exposure is Excellent; Pharmacotherapy is Poor. ### Why Option C is WRONG SSRIs are **not** first-line for specific phobia, and they are **not superior** to psychotherapy. Exposure therapy is the evidence-based gold standard. Medications play only a minor adjunctive role (e.g., to reduce anticipatory anxiety during exposure initiation). [cite:DSM-5 Anxiety Disorders], [cite:Kaplan & Sadock 11e Ch 8]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.